 NORCROSS, Ga., Jan. 06, 2022 GLOBE NEWSWIRE -- Galectin Therapeutics Inc. NASDAQ: GALT, the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. Mr. Joel Lewis, President and Chief Executive Officer, and Dr. Pol F. Boudes, Chief Medical Officer, will be presenting on behalf of the Company. 